Industry Verticals »

All Categories

Insights »

About TMR »

Proliferative Diabetic Retinopathy Market

Proliferative Diabetic Retinopathy Market (Drug Class – Anti-VEGF Agents, Corticosteroids; Application – Treatment of Proliferative Diabetic Retinopathy, Diabetic Macular Edema Management, Retinal Neovascularization Management, Vision Loss Prevention, Post-surgical Disease Management; Mode of Administration – Injectable, Oral, Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2026–2036

Proliferative Diabetic Retinopathy Market Outlook 2036

The Proliferative Diabetic Retinopathy Market was valued at USD 3.1 Billion in 2025 and is expected to reach USD 7.8 Billion by 2036, growing at a CAGR of 9.7% from 2026 to 2036. Growth in the market is attributed to increasing prevalence of diabetes, rising burden of diabetic eye complications, expanding use of retinal screening, and increasing use of intravitreal therapies in vision-threatening retinal complications. Demand is further supported by the increased awareness of the importance of the early diagnosis of diabetic retinopathy, enhanced access to ophthalmology services and ongoing innovations in the treatment of retinal diseases.

Market Size & Highlights

  • The Proliferative Diabetic Retinopathy Market reached USD 3.1 Billion in 2025.
  • The market is expected to reach USD 7.8 Billion by 2036.
  • The proliferative diabetic retinopathy industry is anticipated to expand at a CAGR of 9.7% from 2026 to 2036.
  • Major companies in the proliferative diabetic retinopathy industry include F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., Novartis AG, Bayer AG, and AbbVie Inc.
  • By Drug Class, Anti-VEGF Therapy dominated the market in 2025, holding a revenue share of 57.0%.
  • By Region, North America dominated the market in 2025, holding a revenue share of 42.0%.

Proliferative Diabetic Retinopathy Market By Revenue

Analysts’ Viewpoint on the Proliferative Diabetic Retinopathy Market

Rising prevalence of diabetes and diabetic eye diseases such as diabetic retinopathy is anticipated to drive the proliferative diabetic retinopathy market. Advanced diabetic retinopathy is characterized by the formation of new blood vessels (angiogenesis) at the surface of the retina, and extravasation from these new vessels that can lead to scarring, retinal detachment and loss of vision. Early detection and intervention of such individuals, therefore, is vital.

Anti-VEGF therapy is expected to remain a leading treatment option since VEGF is a crucial component when it comes to the formation of blood vessels that have not formed correctly in the retina. Anti-VEGF agents are now widely used for numerous retinal conditions in which they inhibit the formation of new vessels and leakage of existing vessels. The National Eye Institute said that diabetic retinopathy is a disease that affects the blood vessels in the retina.

The North America region is expected to hold the dominant position due to high cases of diabetes, well-established ophthalmology industry, availability of intravitreal injection therapies, and advanced retinal therapies. Competition will center on long-lasting anti-VEGF therapy, corticosteroid implants, sustained delivery systems, retinal imaging systems, and treatment compliance. Ophthalmology firms that possess strong product portfolio and evidence are likely to enjoy a superior market position.

Proliferative Diabetic Retinopathy Market Introduction

The Proliferative Diabetic Retinopathy Market is classified on the basis of treatment into therapies for late-stage diabetic retinopathy, where abnormal new blood vessels develop on the retina, this is a serious form of diabetic eye disease. These fine blood vessels could cause vitreous hemorrhage, retinal detachment, along with substantial loss of vision. Treatment options include anti-VEGF agents, corticosteroids and other injectable treatments and in certain additional ophthalmic treatment categories, which are applied in the hospital, ophthalmology practice, retina specialty center and ASC market sectors. The increasing prevalence of diabetes, escalating burden of diabetic retinopathy, vision loss prevention and technological advancements in retinal disease therapy, treatment of diabetic macular edema (DME), diabetic eye care and ophthalmology therapeutics are propelling the market growth.

Attribute Detail
Proliferative Diabetic Retinopathy Market Drivers
  • Rising Diabetes Burden Supports Market Growth
  • Increasing Vision-threatening Diabetic Retinopathy Cases Boost Market Growth

Rising Diabetes Burden Supports Market Growth

Contributing factors for the growth of Proliferative Diabetic Retinopathy market is high prevalence of increasing diabetes cases. Diabetes also slowly damages the tiny blood vessels in your retina (diabetic retinopathy), and in late stages, this condition is known as proliferative diabetic retinopathy. The increasing diabetic population will also likely boost the demand for patients to have their retina screened, monitored, and treated.

Diabetes is a long term condition that happens either because the pancreas does not produce enough insulin or because the body cannot effectively use the insulin it makes, says WHO. “WHO also points to global initiatives such as the Global Diabetes Compact and diabetes coverage targets the World Health Assembly has adopted for 2030 as means of maintaining a steady international focus on preventing and managing diabetes.”

The association between diabetes and eye disease makes the provision of ophthalmology services an essential requirement. Diabetic retinopathy Treats blood vessels in the retina National Eye Institute's Diabetic Retinopathy and You Diabetic retinopathy is a problem of the blood vessels in the retina and can lead to vision loss and blindness in people with diabetes. This drives the needs for the treatment products, anti-VEGF agents, corticosteroids, and also for the diagnostic product, retinal imaging, laser treatment, and disease monitoring.

Market growth can also be attributed to advancement in healthcare systems catering early screening and management of chronic diseases. Those at the highest risk for diabetic eye disease are people with long-standing diabetes, individuals with poor blood sugar control, high blood pressure, and kidney disease. Due to developing trends in the diabetes care, demand for proliferative diabetic retinopathy treatment services is likewise expected to enhance that among hospitals, ophthalmology centers and retina specialty centers.

Increasing Vision-threatening Diabetic Retinopathy Cases Boost Market Growth

The rising incidences of patients with vision-threatening diabetic retinopathy is also expected to boost the Proliferative Diabetic Retinopathy Market Development. Proliferative diabetic retinopathy (PDR) is the third and final stage of diabetic eye disease and may lead to blindness, if left untreated. A burgeoning population of females undergoing treatment for neovascularization of the retina, vitreous haemorrhage, diabetic macular oedema or at risk of retinal detachment is reported as well.

The CDC’s Vision and Eye Health Surveillance System, U.S. 9.6 Million People of U.S. were impacted by Diabetic Retinopathy. Among these, 1.84 million were living with vision-threatening diabetic retinopathy. The CDC also reported that the highest percentage of diabetic retinopathy was observed in the 65-79 age group (28.4%) for diabetes patients.

These numbers indicate the necessity for high-level retinal intervention and follow-up. Anti-VEGF injections are the standard of care to treat retinal neovascularization and its complications, while corticosteroids may be used in particular cases, mainly when there is associated inflammation or cystoid macular edema. The demand is likely to increase as a higher number of patients are identified through screening programs, retinal imaging and specialist referrals.

The market is also being driven by treatment trends that focus on reducing the injection burden and improving patient adherence. Sustained-release platforms and longer-acting retinal agents are being developed to facilitate better disease management, in particular for patients requiring repeat long-term treatment and follow-up visits.

Attribute Detail
Proliferative Diabetic Retinopathy Market Opportunities
  • Longer-acting Retinal Therapies and Sustained-release Drug Delivery Create New Growth Space in the Market

Longer-acting Retinal Therapies and Sustained-release Drug Delivery Create New Growth Space

Long-acting retinal therapeutics and sustained drug delivery are emerging as new horizons in the Proliferative Diabetic Retinopathy Market. Treatment today often demands a series of intravitreal injections and frequent visits to a specialist. That translates to a burden for patients, their caregivers and retina clinics. Treatments that can prolong the interval between doses, improve durability and maintain disease control will be well received.

In May 2025, Roche announced that by U.S. FDA approval of Susvimo® in diabetic retinopathy. Roche announced that Susvimo® can enable people with diabetic retinopathy to preserve sight and reduce the risk of blindness with a single treatment every nine months. The company also announced that diabetic retinopathy impacts nearly 10 million individuals in the U.S. and over 100 million worldwide.

Roche will present over 45 abstracts at ARVO 2026, including novel data from its ophthalmology portfolio, the company announced in April 2026. The company's data highlights real-world data for Vabysmo in diabetic macular edema and Susvimo data that the implant may provide a path to lasting disease control with continuous delivery while reducing treatment burden.

Such developments reflect a shift of the market towards long-acting retinal disease treatments and patient convenience. Providers of next generation anti-VEGF therapies, corticosteroid implants, sustained-release systems, and clinically substantiated ophthalmology products are anticipated to benefit from increasing demand for long-term management of diabetic eye disease.

Anti-VEGF Therapy Leads the Proliferative Diabetic Retinopathy Market by Drug Class

Proliferative Diabetic Retinopathy Market By Type

Attribute Detail
Leading Drug Class
  • Anti-VEGF Therapy

Anti-VEGF Therapy is expected to dominate the industry with a share of 57.0% in 2025 in the Proliferative Diabetic Retinopathy Market. VEGF inhibitors are now the standard of care for diabetic retinal disease because they inhibit vascular endothelial growth factor, a protein that stimulates the growth of abnormal blood vessels and leakage in the retina.

This segment is driven by strong adoption in retinal disease management, well established application in intravitreal injection therapy and growing demand for advanced ophthalmology therapeutics. Anti-VEGF therapy is also used in a wide variety of other clinical applications such as proliferative diabetic retinopathy, treatment for diabetic macular edema, management of retinal neo-vascularization and prevention of vision loss. It is further propelled by an increasing diabetic retinopathy screening, growing referral to retina specialist, and greater penetration of ophthalmic drugs in hospitals, ophthalmology clinics, and retina centers.

Product innovation is directed at long-acting anti-VEGF agents, sustained retinal disease treatment, and elimination of the injection burden through enhanced patient adherence. These trends are projected to further augment Anti-VEGF Therapy's dominance in the Proliferative Diabetic Retinopathy market over the forecast period.

North America Leads the Proliferative Diabetic Retinopathy Market by Region

Proliferative Diabetic Retinopathy Market By Region

Attribute Detail
Leading Region
  • North America

North America is a leading region in the proliferative diabetic retinopathy market, occupying approximately 42.0% of the share in 2025. The region’s superiority can be attributed to a number of factors, including a high diabetes population, good retinal care infrastructure, established reimbursement policies for ophthalmology services, and easy-to-access anti-VEGF and corticosteroid-based treatment options.

The presence of robust ophthalmology networks, specialized centers for the retina, diabetic retinopathy screening programs, as well as early and high utilization of intravitreal injection therapy make the region of advantage. These aspects result in continuous demand for treatment of retinal diseases, diabetic eye care, therapeutics in ophthalmology, and prevention of vision loss.

North America is also anticipated to witness steady growth as a result of the increasing emphasis on early diagnosis, disease monitoring, specialized care, and availability of novel ophthalmic drugs in this region. Increasing uptake of extended duration retinal therapies, enhanced treatment adherence and broader availability of retina experts will fuel regional market growth in the forecast period.

Analysis of Key Players in the Proliferative Diabetic Retinopathy Market

F. Hoffmann-La Roche Ltd., Genentech, Inc., Regeneron Pharmaceuticals, Inc., Novartis AG, Bayer AG, AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., ANI Pharmaceuticals, Inc., Pfizer Inc., Merck KGaA, Cipla Inc., Intas Pharmaceuticals Ltd., EyePoint Pharmaceuticals, Inc., Kodiak Sciences Inc., Oculis Holding AG, REGENXBIO Inc., Opthea Limited, Clearside Biomedical, Inc., and Oxurion NV and others are some of the leading companies operating in the global Proliferative Diabetic Retinopathy market.

Each of these companies has been profiled in the Proliferative Diabetic Retinopathy market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, ophthalmology pipeline, regulatory approvals, and recent developments.

Key Developments in the Proliferative Diabetic Retinopathy Market

  • In April 2026, Roche announced that it would present extensive ophthalmology portfolio data at ARVO 2026. The company highlighted real-world Vabysmo data in diabetic macular edema and key Susvimo data showing the potential for lasting disease control through continuous delivery while reducing treatment burden.
  • In February 2026, Regeneron Pharmaceuticals, Inc. announced EYLEA HD® presentations at the Angiogenesis, Exudation, and Degeneration 2026 meeting. The company stated that the presentations included clinical data supporting the efficacy and safety of EYLEA HD for serious retinal diseases.
  • In May 2025, Roche announced that the U.S. FDA approved Susvimo® for diabetic retinopathy. The company stated that Susvimo can help people with diabetic retinopathy maintain vision and prevent progression to blindness with one treatment every nine months.

Proliferative Diabetic Retinopathy Market Snapshot

Attribute Detail
Market Size Value in 2025 (Base Year) USD 3.1 Billion
Market Forecast Value in 2036 USD 7.8 Billion
Growth Rate (CAGR 2026-2036) 9.7%
Forecast Period 2026-2036
Historical Data Available for 2021-2025
Quantitative Units USD Billion for Value
Proliferative Diabetic Retinopathy Market Analysis It includes segment analysis as well as regional-level analysis. Qualitative analysis includes drivers, restraints, opportunities, key trends, regulatory analysis, pipeline analysis, and competitive analysis.
Competition Landscape
  • Competition Matrix
  • Company profiles section includes overview, product portfolio, ophthalmology pipeline, regulatory approvals, sales footprint, strategy & recent developments, and key financials
Format
  • Electronic (PDF) + Excel
Segmentation By Drug Class
  • Anti-VEGF Agents
  • Corticosteroids
By Mode of Administration
  • Injectable
  • Oral
  • Others
By Application
  • Treatment of Proliferative Diabetic Retinopathy
  • Diabetic Macular Edema Management
  • Retinal Neovascularization Management
  • Vision Loss Prevention
  • Post-surgical Disease Management
By End-user By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • The Netherlands
  • Switzerland
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • Brazil
  • Mexico
  • Argentina
  • GCC Countries
  • South Africa
Companies Profiled
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG
  • Bayer AG
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Santen Pharmaceutical Co., Ltd.
  • ANI Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Merck KGaA
  • Cipla Inc.
  • Intas Pharmaceuticals Ltd.
  • EyePoint Pharmaceuticals, Inc.
  • Kodiak Sciences Inc.
  • Oculis Holding AG
  • REGENXBIO Inc.
  • Opthea Limited
  • Clearside Biomedical, Inc.
  • Oxurion NV
  • Other Key Players
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

What is the market size of the Proliferative Diabetic Retinopathy Market?

The global Proliferative Diabetic Retinopathy Industry was valued at USD 3.1 Billion in 2025.

What is the forecast value of the Proliferative Diabetic Retinopathy Market by 2036?

The global Proliferative Diabetic Retinopathy Industry is projected to reach USD 7.8 Billion by 2036.

What is the CAGR of the Proliferative Diabetic Retinopathy Market?

The Proliferative Diabetic Retinopathy Market is expected to expand at a CAGR of 9.7% from 2026 to 2036.

Which drug class leads the Proliferative Diabetic Retinopathy Market?

Anti-VEGF Therapy leads the market with a 57.0% share in 2025.

Which region dominates the Proliferative Diabetic Retinopathy Market?

North America dominates the Proliferative Diabetic Retinopathy Market with a 42.0% revenue share in 2025.

Who are the major companies in the Proliferative Diabetic Retinopathy Industry?

Major companies operating in the Proliferative Diabetic Retinopathy Industry include F. Hoffmann-La Roche Ltd., Genentech, Inc., Regeneron Pharmaceuticals, Inc., Novartis AG, Bayer AG, AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., ANI Pharmaceuticals, Inc., Pfizer Inc., Merck KGaA, Cipla Inc., Intas Pharmaceuticals Ltd., EyePoint Pharmaceuticals, Inc., Kodiak Sciences Inc., Oculis Holding AG, REGENXBIO Inc., Opthea Limited, Clearside Biomedical, Inc., and Oxurion NV

  1. Preface
    • Market Definition and Scope
    • Market Segmentation
    • Key Research Objectives
    • Research Highlights
  2. Assumptions and Research Methodology
  3. Executive Summary: Global Proliferative Diabetic Retinopathy Market
  4. Market Overview
    • Introduction
      • Segment Definition
      • Industry Evolution / Developments
    • Overview
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunities
    • Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, 2021-2036
      • Market Revenue Projections (USD Billion)
  5. Key Insights
    • Technology Adoption Analysis
    • Regulatory and Market Access Assessment
    • Epidemiology and Disease Burden Analysis
    • Screening and Early Diagnosis Trends
    • Treatment Algorithm Evolution
    • Anti-VEGF Therapy Adoption Analysis
    • Reimbursement and Pricing Landscape Assessment
    • Strategic Partnerships, Licensing, and M&A Activity Assessment
    • Future Market Outlook and Innovation Trends
  6. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Drug Class
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Attractiveness Analysis, by Drug Class
  7. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Mode of Administration
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Attractiveness Analysis, by Mode of Administration
  8. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Application
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Attractiveness Analysis, by Application
  9. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by End-user
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Attractiveness Analysis, by End-user
  10. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Distribution Channel
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis, by Distribution Channel
  11. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Region
    • Key Findings
    • Market Value Forecast, by Region, 2021-2036
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East and Africa
    • Market Attractiveness Analysis, by Region
  12. North America Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Value Forecast, by Country, 2021-2036
      • U.S.
      • Canada
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
      • By Country
  13. U.S. Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  14. Canada Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  15. Europe Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Value Forecast, by Country/Sub-region, 2021-2036
      • Germany
      • U.K
      • France
      • Italy
      • Spain
      • Switzerland
      • The Netherlands
      • Rest of Europe
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
      • By Country/Sub-region
  16. Germany Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  17. U.K Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  18. France Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  19. Italy Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  20. Spain Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  21. Switzerland Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  22. The Netherlands Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  23. Rest of Europe Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  24. Asia Pacific Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Value Forecast, by Country/Sub-region, 2021-2036
      • China
      • India
      • Japan
      • South Korea
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
      • By Country/Sub-region
  25. China Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  26. India Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  27. Japan Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  28. South Korea Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  29. Australia & New Zealand Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  30. Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  31. Latin America Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Value Forecast, by Country/Sub-region, 2021-2036
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
      • By Country/Sub-region
  32. Brazil Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  33. Mexico Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  34. Argentina Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  35. Rest of Latin America Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  36. Middle East and Africa Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Value Forecast, by Country/Sub-region, 2021-2036
      • GCC Countries
      • South Africa
      • Rest of Middle East and Africa
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
      • By Country/Sub-region
  37. GCC Countries Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  38. South Africa Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  39. Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Drug Class, 2021-2036
      • Anti-VEGF Agents
      • Corticosteroids
    • Market Value Forecast, by Mode of Administration, 2021-2036
      • Injectable
      • Oral
      • Others
    • Market Value Forecast, by Application, 2021-2036
      • Treatment of Proliferative Diabetic Retinopathy
      • Diabetic Macular Edema Management
      • Retinal Neovascularization Management
      • Vision Loss Prevention
      • Post-surgical Disease Management
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Ophthalmology Clinics
      • Retina Specialty Centers
      • Ambulatory Surgical Centers
      • Others
    • Market Value Forecast, by Distribution Channel, 2021-2036
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Market Attractiveness Analysis
      • By Drug Class
      • By Mode of Administration
      • By Application
      • By End-user
      • By Distribution Channel
  40. Competition Landscape
    • Market Player - Competition Matrix (By Tier and Size of Companies)
    • Market Share Analysis, by Company (2025)
    • Company Profiles
      • F. Hoffmann-La Roche Ltd.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Genentech, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Regeneron Pharmaceuticals, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Novartis AG
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Bayer AG
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • AbbVie Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Bausch Health Companies Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Santen Pharmaceutical Co., Ltd.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • ANI Pharmaceuticals, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Pfizer Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Merck KGaA
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Cipla Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Intas Pharmaceuticals Ltd.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • EyePoint Pharmaceuticals, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Kodiak Sciences Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Oculis Holding AG
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • REGENXBIO Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Opthea Limited
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Clearside Biomedical, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Oxurion NV
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments

List of Table

Table 01: Global Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 02: Global Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 03: Global Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 04: Global Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 05: Global Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 06: Global Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 07: North America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 08: North America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 09: North America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 10: North America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 11: North America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 12: North America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Country, 2021 to 2036
Table 13: U.S. Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 14: U.S. Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 15: U.S. Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 16: U.S. Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 17: U.S. Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 18: Canada Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 19: Canada Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 20: Canada Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 21: Canada Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 22: Canada Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 23: Europe Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 24: Europe Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 25: Europe Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 26: Europe Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 27: Europe Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 28: Europe Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 29: Germany Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 30: Germany Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 31: Germany Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 32: Germany Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 33: Germany Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 34: U.K. Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 35: U.K. Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 36: U.K. Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 37: U.K. Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 38: U.K. Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 39: France Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 40: France Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 41: France Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 42: France Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 43: France Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 44: Italy Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 45: Italy Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 46: Italy Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 47: Italy Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 48: Italy Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 49: Spain Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 50: Spain Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 51: Spain Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 52: Spain Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 53: Spain Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 54: Switzerland Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 55: Switzerland Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 56: Switzerland Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 57: Switzerland Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 58: Switzerland Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 59: The Netherlands Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 60: The Netherlands Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 61: The Netherlands Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 62: The Netherlands Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 63: The Netherlands Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 64: Rest of Europe Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 65: Rest of Europe Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 66: Rest of Europe Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 67: Rest of Europe Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 68: Rest of Europe Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 69: Asia Pacific Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 70: Asia Pacific Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 71: Asia Pacific Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 72: Asia Pacific Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 73: Asia Pacific Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 74: Asia Pacific Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 75: China Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 76: China Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 77: China Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 78: China Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 79: China Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 80: Japan Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 81: Japan Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 82: Japan Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 83: Japan Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 84: Japan Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 85: India Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 86: India Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 87: India Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 88: India Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 89: India Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 90: South Korea Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 91: South Korea Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 92: South Korea Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 93: South Korea Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 94: South Korea Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 95: Australia and New Zealand Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 96: Australia and New Zealand Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 97: Australia and New Zealand Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 98: Australia and New Zealand Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 99: Australia and New Zealand Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 100: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 101: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 102: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 103: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 104: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 105: Latin America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 106: Latin America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 107: Latin America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 108: Latin America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 109: Latin America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 110: Latin America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 111: Brazil Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 112: Brazil Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 113: Brazil Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 114: Brazil Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 115: Brazil Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 116: Mexico Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 117: Mexico Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 118: Mexico Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 119: Mexico Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 120: Mexico Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 121: Argentina Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 122: Argentina Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 123: Argentina Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 124: Argentina Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 125: Argentina Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 126: Rest of Latin America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 127: Rest of Latin America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 128: Rest of Latin America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 129: Rest of Latin America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 130: Rest of Latin America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 131: Middle East and Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 132: Middle East and Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 133: Middle East and Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 134: Middle East and Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 135: Middle East and Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 136: Middle East and Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 137: GCC Countries Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 138: GCC Countries Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 139: GCC Countries Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 140: GCC Countries Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 141: GCC Countries Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 142: South Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 143: South Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 144: South Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 145: South Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 146: South Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036
Table 147: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Drug Class, 2021 to 2036
Table 148: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Mode of Administration, 2021 to 2036
Table 149: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 150: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 151: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, by Distribution Channel, 2021 to 2036

List of Figure

Figure 01: Global Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 02: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 03: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 04: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Anti-VEGF Agents, 2021 to 2036
Figure 05: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Corticosteroids, 2021 to 2036
Figure 06: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 07: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 08: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Injectable, 2021 to 2036
Figure 09: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Oral, 2021 to 2036
Figure 10: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Others, 2021 to 2036
Figure 11: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 12: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 13: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Treatment of Proliferative Diabetic Retinopathy, 2021 to 2036
Figure 14: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Diabetic Macular Edema Management, 2021 to 2036
Figure 15: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Retinal Neovascularization Management, 2021 to 2036
Figure 16: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Vision Loss Prevention, 2021 to 2036
Figure 17: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Post-surgical Disease Management, 2021 to 2036
Figure 18: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 19: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 20: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Hospitals, 2021 to 2036
Figure 21: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Ophthalmology Clinics, 2021 to 2036
Figure 22: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Retina Specialty Centers, 2021 to 2036
Figure 23: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Ambulatory Surgical Centers, 2021 to 2036
Figure 24: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Others, 2021 to 2036
Figure 25: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 26: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 27: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Hospital Pharmacies, 2021 to 2036
Figure 28: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Retail Pharmacies, 2021 to 2036
Figure 29: Global Proliferative Diabetic Retinopathy Market Revenue (USD Billion), by Online Pharmacies, 2021 to 2036
Figure 30: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 31: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 32: North America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 33: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 34: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 35: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 36: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 37: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 38: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 39: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 40: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 41: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 42: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 43: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country, 2025 and 2036
Figure 44: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country, 2026 to 2036
Figure 45: U.S. Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 46: U.S. Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 47: U.S. Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 48: U.S. Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 49: U.S. Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 50: U.S. Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 51: U.S. Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 52: U.S. Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 53: U.S. Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 54: U.S. Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 55: U.S. Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 56: Canada Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 57: Canada Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 58: Canada Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 59: Canada Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 60: Canada Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 61: Canada Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 62: Canada Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 63: Canada Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 64: Canada Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 65: Canada Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 66: Canada Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 67: Europe Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 68: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 69: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 70: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 71: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 72: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 73: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 74: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 75: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 76: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 77: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 78: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 79: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 80: Germany Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 81: Germany Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 82: Germany Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 83: Germany Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 84: Germany Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 85: Germany Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 86: Germany Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 87: Germany Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 88: Germany Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 89: Germany Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 90: Germany Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 91: U.K. Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 92: U.K. Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 93: U.K. Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 94: U.K. Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 95: U.K. Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 96: U.K. Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 97: U.K. Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 98: U.K. Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 99: U.K. Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 100: U.K. Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 101: U.K. Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 102: France Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 103: France Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 104: France Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 105: France Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 106: France Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 107: France Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 108: France Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 109: France Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 110: France Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 111: France Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 112: France Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 113: Italy Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 114: Italy Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 115: Italy Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 116: Italy Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 117: Italy Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 118: Italy Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 119: Italy Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 120: Italy Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 121: Italy Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 122: Italy Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 123: Italy Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 124: Spain Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 125: Spain Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 126: Spain Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 127: Spain Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 128: Spain Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 129: Spain Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 130: Spain Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 131: Spain Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 132: Spain Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 133: Spain Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 134: Spain Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 135: Switzerland Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 136: Switzerland Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 137: Switzerland Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 138: Switzerland Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 139: Switzerland Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 140: Switzerland Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 141: Switzerland Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 142: Switzerland Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 143: Switzerland Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 144: Switzerland Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 145: Switzerland Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 146: The Netherlands Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 147: The Netherlands Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 148: The Netherlands Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 149: The Netherlands Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 150: The Netherlands Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 151: The Netherlands Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 152: The Netherlands Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 153: The Netherlands Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 154: The Netherlands Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 155: The Netherlands Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 156: The Netherlands Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 157: Rest of Europe Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 158: Rest of Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 159: Rest of Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 160: Rest of Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 161: Rest of Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 162: Rest of Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 163: Rest of Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 164: Rest of Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 165: Rest of Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 166: Rest of Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 167: Rest of Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 168: Asia Pacific Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 169: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 170: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 171: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 172: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 173: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 174: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 175: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 176: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 177: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 178: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 179: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 180: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 181: China Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 182: China Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 183: China Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 184: China Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 185: China Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 186: China Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 187: China Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 188: China Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 189: China Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 190: China Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 191: China Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 192: Japan Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 193: Japan Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 194: Japan Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 195: Japan Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 196: Japan Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 197: Japan Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 198: Japan Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 199: Japan Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 200: Japan Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 201: Japan Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 202: Japan Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 203: India Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 204: India Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 205: India Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 206: India Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 207: India Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 208: India Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 209: India Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 210: India Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 211: India Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 212: India Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 213: India Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 214: South Korea Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 215: South Korea Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 216: South Korea Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 217: South Korea Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 218: South Korea Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 219: South Korea Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 220: South Korea Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 221: South Korea Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 222: South Korea Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 223: South Korea Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 224: South Korea Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 225: Australia and New Zealand Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 226: Australia and New Zealand Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 227: Australia and New Zealand Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 228: Australia and New Zealand Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 229: Australia and New Zealand Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 230: Australia and New Zealand Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 231: Australia and New Zealand Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 232: Australia and New Zealand Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 233: Australia and New Zealand Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 234: Australia and New Zealand Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 235: Australia and New Zealand Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 236: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 237: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 238: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 239: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 240: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 241: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 242: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 243: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 244: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 245: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 246: Rest of Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 247: Latin America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 248: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 249: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 250: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 251: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 252: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 253: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 254: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 255: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 256: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 257: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 258: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 259: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 260: Brazil Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 261: Brazil Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 262: Brazil Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 263: Brazil Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 264: Brazil Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 265: Brazil Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 266: Brazil Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 267: Brazil Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 268: Brazil Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 269: Brazil Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 270: Brazil Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 271: Mexico Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 272: Mexico Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 273: Mexico Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 274: Mexico Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 275: Mexico Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 276: Mexico Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 277: Mexico Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 278: Mexico Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 279: Mexico Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 280: Mexico Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 281: Mexico Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 282: Argentina Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 283: Argentina Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 284: Argentina Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 285: Argentina Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 286: Argentina Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 287: Argentina Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 288: Argentina Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 289: Argentina Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 290: Argentina Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 291: Argentina Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 292: Argentina Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 293: Rest of Latin America Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 294: Rest of Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 295: Rest of Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 296: Rest of Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 297: Rest of Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 298: Rest of Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 299: Rest of Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 300: Rest of Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 301: Rest of Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 302: Rest of Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 303: Rest of Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 304: Middle East and Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 305: Middle East and Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 306: Middle East and Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 307: Middle East and Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 308: Middle East and Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 309: Middle East and Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 310: Middle East and Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 311: Middle East and Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 312: Middle East and Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 313: Middle East and Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 314: Middle East and Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 315: Middle East and Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 316: Middle East and Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 317: GCC Countries Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 318: GCC Countries Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 319: GCC Countries Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 320: GCC Countries Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 321: GCC Countries Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 322: GCC Countries Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 323: GCC Countries Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 324: GCC Countries Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 325: GCC Countries Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 326: GCC Countries Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 327: GCC Countries Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 328: South Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 329: South Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 330: South Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 331: South Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 332: South Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 333: South Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 334: South Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 335: South Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 336: South Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 337: South Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 338: South Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036
Figure 339: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Value (USD Billion) Forecast, 2021 to 2036
Figure 340: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2025 and 2036
Figure 341: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2026 to 2036
Figure 342: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2025 and 2036
Figure 343: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2026 to 2036
Figure 344: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Application, 2025 and 2036
Figure 345: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 346: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by End-user, 2025 and 2036
Figure 347: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 348: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2025 and 2036
Figure 349: Rest of Middle East and Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2026 to 2036

Copyright © Transparency Market Research, Inc. All Rights reserved

Proliferative Diabetic Retinopathy Market

Buy This ReportBuy Now